Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. 3. Prospective collection of data: data were collected according to a protocol established before the beginning of the study 4. End points appropriate to the aim of the study: unambiguous explanation of the criteria used to evaluate the main outcome which should be in accordance with the question addressed by the study. In addition, the end points should be assessed on an intention-to-treat basis 5. Unbiased assessment of the study end point: blind evaluation of objective end points and double-blind evaluation of subjective end points. Otherwise, the reasons for not blinding should be stated 6. Follow-up period appropriate to the aim of the study: the follow-up should be sufficiently long to allow the assessment of the main endpoint and possible adverse events 7. Loss to follow-up less than 5%: all patients should be included in the follow-up. Otherwise, the proportion lost to follow-up should not exceed the proportion experiencing the major end point 8. Prospective calculation of the study size: information of the size of detectable difference of interest with a calculation of 95% CI, according to the expected incidence of the outcome event, and information about the level for statistical a This study reported being a level II study but we have classified this case series with failure analysis as level IV study
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